Synbio Technologies LLC services

Immune Repertoire refers to the set of all functionally diversified B cells and T cells in the circulatory system of an individual at any given time. Immune repertoire sequencing (Immuno-Seq) targets at T/B lymphocytes and utilizes the 5’ Rapid Amplification of cDNA Ends (RACE) Technology. The 5’ RACE technology amplifies complementarity-determining regions (CDRs) of B cell receptors (BCRs) or T cell receptors (TCRs). The CDRs are targeted because they control the diversity of the corresponding BCRs and TCRs. Combined with the high-throughput sequencing technology, the Immuno-Seq provides a comprehensive evaluation of the immune system diversity.

Obtaining the hybridoma monoclonal antibody (mAb) sequence is one of the key requirements of recombinant antibody engineering. Synbio Technologies provides both accurate and efficient monoclonal antibody sequencing services. To accomplish this, we utilize special primer sets and advanced sequencing techniques to help our customers save on research costs and increase overall efficiency. In doing so, we allow our customers to accomplish their downstream research goals and applications such as antibody humanization, antibody reformatting, or cell line transfection.

Accurately acquiring antibody sequences is one of the most important prerequisites to achieving antibody functional optimization and expression of recombinant engineering antibodies. Antibody sequencing and analysis also plays a key role for researchers publishing articles and apply for patents. The data is even more critical for pharmaceutical enterprises to further their research and develop novel drugs. Synbio Technologies can quickly and accurately sequence and analyze antibody sequences with our advanced Geno^TM Ab Platform. Using this platform, we can perform high quality de novo sequencing of multi-species’ (including mice, rats, Armenian hamsters, camels, rabbits, equines, bovines, canines, birds, etc.) monoclonal antibodies.

In recent years, the proportion of biological drugs in the global pharmaceutical market has been close to 20%. The focus within the global pharmaceutical market has been gradually shifting from small molecule chemical drugs to biomacromolecules (biological drugs). It also appears that the trend is gradually expanding. Biological drugs are a broad class of pharmaceuticals generated by using principles and methods of biology, immunology, physical chemistry, and pharmacology, etc. These drugs utilize the composition of various organisms and biological tissues, as well as organs. Biological drugs usually include genetic engineering drugs, antibody engineering drugs, blood products drugs, and vaccines etc. Among these, antibody drugs are one of the fastest growing human therapeutic drugs.

Hybridoma technology features the effective usage of innate functions of both immune and cancer cells to generate monoclonal antibodies (mAbs). The resulting hybridoma cell lines are produced to combat specific antigens of interest. Such technology has forged remarkable new approaches toward therapeutic mAb discovery, as well as disease diagnosis and prevention.

Immunogenicity or Human Anti-Mouse Antibodies (HAMA) response is what happens when antibodies derived from xenogeneic sources are administered to humans. This can potentially decrease the effectiveness of immune-treatment through rapid clearance of the therapeutic antibody or immune-conjugate. In some cases, the patient may even develop an allergic sensitivity and be at risk of anaphylactic shock upon any future treatment containing these “foreign” antibodies. Due to this potential risk of immunogenicity and HAMA response, the humanization of antibodies from xenogeneic sources to become safer and more reliable humanized antibody drugs is critical.

The binding affinity of an antibody is one of the key parameters to determine the efficacy and dosage of an antibody drug. Currently, the methods for improving the binding affinity of antibodies mainly focus on site-mutation, CDR rearrangement, DNA recombinant, etc. With our unique and effective affinity maturation technology, we can quickly spot the key amino acid site in antibody domain. This, in turn, increases the binding affinity of the antibody, reaching at least nM level.

Complex structures and high production costs associated with monoclonal antibodies (mAbs) have limited their achievable clinical applications. For this reason, scientists focusing on antibody drug discovery have shifted their interests toward recombinant antibody fragments.

The immune system is a very robust “antibody factory” that consistently produces antibodies to fight infections and diseases by recognizing and targeting infected cells or pathogens (antigens). The emergence of single B cell antibody technology has enabled a new strategy for discovery of naturally occurring antibody drugs. The single B cell antibody technology produces higher throughput and higher coverage than the conventional hybridoma or phage display technologies. Most importantly, this technology also avoids the disadvantage of unnaturally paired heavy and light antibody chain displayed by phage.

miRNAs are single stranded small non-coding RNA of 22 nucleotides that play important roles as endogenous gene regulators by mediating translation repression or promoting degradation of target mRNA. While the normal expression and function of miRNAs are vital for physiological processes, aberrant expression of miRNAs has been proved to be closely related to the occurrence of various cancers. Perturbation of endogeneous miRNAs helps to study the function of specific miRNAs and holds the potential for therapeutics. Synbio Technologies offers a wide range of high quality miRNA synthesis products, including miRNA inhibitors/mimics, miRNA agomirs/antagomirs and miRNA negative controls, etc. to support your miRNA functional research.